Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 13/20 | 0.53 |
| ▸ | EGFR | P00533 | 7/20 | 0.48 |
| ▸ | JAK3 | P52333 | 2/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.45 |
| ▸ | BMX | P51813 | 1/20 | 0.45 |
| ▸ | BTK | Q06187 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21747790 | 1.00 | ERBB2 (0.53) | ERBB2EGFRJAK3MTORBMX | |
| Trifluoroacetic Acid SCHEMBL21747824 | 0.95 | ERBB2 (0.49) | ERBB2EGFRJAK3MTORBMX | |
| SCHEMBL21747839 | 0.92 | ERBB2 (0.52) | ERBB2EGFRJAK3MTORBMX | |
| SCHEMBL29700821 | 0.92 | ERBB2 (0.52) | ERBB2EGFRJAK3MTORBMX | |
| SCHEMBL21747882 | 0.91 | JAK3 (0.45) | ERBB2EGFRJAK3MTORBMX | |
| SCHEMBL30090123 | 0.90 | ERBB2 (0.53) | ERBB2EGFRJAK3MTORBMX | |
| SCHEMBL21747792 | 0.90 | ERBB2 (0.53) | ERBB2EGFRJAK3MTORBMX | |
| SCHEMBL29700801 | 0.90 | JAK3 (0.45) | ERBB2EGFRJAK3BTK | |
| SCHEMBL21747924 | 0.90 | JAK3 (0.45) | ERBB2EGFRJAK3BTK | |
| SCHEMBL21747846 | 0.88 | ERBB2 (0.49) | ERBB2EGFRJAK3MTORBMX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3807274-B1 | 4-SUBSTITUTED PYRROLO[2,3-B]PYRIDINE AS ERBB MODULATORS USEFUL FOR TREATING CANCER | LEAD DISCOVERY CENTER GMBH (DE) | 2022-07-27 | — | — | EP | claimed |
| US-20220370440-A1 | 4-SUBSTITUTED PYRROLO[2,3-B]PYRIDINE AS ERBB MODULATORS USEFUL FOR TREATING CANCER | LEAD DISCOVERY CENTER GMBH (DE) | 2022-11-24 | — | — | US | disclosed |
| EP-3807274-B1 | 4-SUBSTITUTED PYRROLO[2,3-B]PYRIDINE AS ERBB MODULATORS USEFUL FOR TREATING CANCER | LEAD DISCOVERY CENTER GMBH (DE) | 2022-07-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220370440-A1 | 4-SUBSTITUTED PYRROLO[2,3-B]PYRIDINE AS ERBB MODULATORS USEFUL FOR TREATING CANCER | ERBB2, ERBB4, ERBB3 | ERBB2 1/4885EGFR 4/4885JAK3 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.